Ultragenyx Pharmaceutical Stock Forecast, Price & News

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

Is Ultragenyx Pharmaceutical a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical or view top-rated stocks.

How has Ultragenyx Pharmaceutical's stock been impacted by Coronavirus?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 81.7% and is now trading at $82.39.
View which stocks have been most impacted by COVID-19.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Ultragenyx Pharmaceutical.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.43) by $0.35. The biopharmaceutical company had revenue of $81.65 million for the quarter, compared to analysts' expectations of $78.16 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 38.25% and a negative net margin of 98.89%. During the same period in the prior year, the firm earned ($1.13) earnings per share.
View Ultragenyx Pharmaceutical's earnings history.

What price target have analysts set for RARE?

15 brokerages have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $73.00 to $179.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $137.65 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:

• Emil D. Kakkis, President, Chief Executive Officer & Director (LinkedIn Profile)
• Mardi C. Dier, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Dennis Karl Huang, Chief Technical Operations Officer & Senior VP (LinkedIn Profile)
• Camille L. Bedrosian, Chief Medical Officer & Executive Vice President (LinkedIn Profile)
• Thomas Richard Kassberg, Chief Business Officer & Executive Vice President

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

Who are some of Ultragenyx Pharmaceutical's key competitors?

Some companies that are related to Ultragenyx Pharmaceutical include Catalent (CTLT), Takeda Pharmaceutical (TKPYY), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND) and CureVac (CVAC).
View all of RARE's competitors.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.06%), Capital Research Global Investors (4.93%), Wellington Management Group LLP (3.68%), Alliancebernstein L.P. (1.70%), Macquarie Group Ltd. (1.37%) and Bank of New York Mellon Corp (1.27%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Millennium Management LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., Two Sigma Investments LP, Morgan Stanley, Cubist Systematic Strategies LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski.
View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Rock Springs Capital Management LP, Invesco Ltd., Janus Henderson Group PLC, Lord Abbett & CO. LLC, Dimensional Fund Advisors LP, Teachers Retirement System of The State of Kentucky, and International Biotechnology Trust PLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $82.39.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical has a market capitalization of $5.62 billion and generates $271.03 million in revenue each year. The biopharmaceutical company earns $-186.57 million in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 893 workers across the globe.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Where are Ultragenyx Pharmaceutical's headquarters?

Ultragenyx Pharmaceutical is headquartered at 60 Leveroni Court, Novato CA, 94949.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810.